Clinical Trials · NCT05477576
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- RayzeBio, Inc.
- Enrollment
- 338
- Start date
- Mar 2022
- Locations
- 54 sites, 8 countries
- Primary endpoint
- Phase 1b: RP3D